TXMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TXMD is not a good buy right now for an impatient investor. Price is sliding hard (-6.09% regular session, further weak pre/post), momentum is deteriorating (MACD histogram negative and expanding), and there is no Intellectia AI Stock Picker or SwingMax buy signal to justify stepping in immediately. While the stock is sitting right on support (～2.15) and insider buying is a meaningful positive, the current tape favors waiting for either a clear reversal off support or a signal-driven entry rather than buying into accelerating downside.
Trend/structure: Short- and medium-term moving averages are still stacked bullishly (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend has been positive, but the near-term momentum has turned down. Momentum: MACD histogram = -0.0312 and negatively expanding → bearish momentum is strengthening. RSI: RSI_6 = 40.08 (neutral-to-weak) → not oversold, so downside can continue before a natural technical bounce. Levels: Key support is S1 ~ 2.15 (price ~2.16 is essentially on it). A clean break below S1 opens room toward S2 ~ 1.945. Upside rebound levels: Pivot ~2.482 then R1 ~2.815. Bottom line: Despite bullish MA stacking, the immediate setup is a pullback with weakening momentum; buying here is betting on a support bounce that is not yet confirmed.
• Insiders are buying: buying amount increased +399.5% over the last month, a strong internal confidence indicator.
• Revenue momentum: 2025/Q3 revenue +43.33% YoY (from a small base).
• Technical location: price is sitting on major near-term support (～2.15), which can trigger a reflex bounce if it holds.
• Potential event catalyst ahead: next earnings on 2026-02-11 (after hours) can re-rate the stock if results surprise positively.
• Sharp near-term selloff: -6.09% regular session plus additional weakness pre/post suggests sellers are in control.
• Momentum deterioration: MACD is negative and worsening; RSI not oversold → pullback can extend.
• Profitability/earnings quality worsened: 2025/Q3 net income and EPS fell sharply YoY.
• No supportive news flow: no recent-week news/catalyst to explain or halt the selloff.
• If support fails: break below ~2.15 increases probability of a move toward ~1.95.
Latest quarter: 2025/Q3. • Revenue: $784K, +43.33% YoY (growth improving, but absolute revenue base remains very small). • Net income: $152K, -124.96% YoY (material deterioration vs prior year). • EPS: $0.01, -120.00% YoY. • Gross margin: reported as 100 (flat YoY per provided snapshot). Takeaway: Top-line growth is strong on paper, but earnings power is not trending in the right direction, which weakens the fundamental support for buying into a downswing.
No analyst rating/price target change data was provided, so there is no confirmed recent trend in upgrades/downgrades or target revisions. Wall Street-style pros vs cons based on available data: Pros: insider accumulation; strong YoY revenue growth; potential bounce at well-defined support. Cons: worsening profitability/EPS; micro-cap/speculative behavior implied by extreme IV; near-term technical momentum is bearish; no fresh catalyst/news support. Influential/Political trading check: No recent congress trading data available (no evidence of politician activity from the provided dataset).
